New active substances authorized in the United Kingdom between 1972 and 1994

Abstract

AimsThe study was undertaken to assemble a list of all new active medicinal substances authorised in the United Kingdom between 1972 and1994; to assess whether the pattern of introductions had changed; and to examine withdrawal rates and the reasons for withdrawal. Methods The identities of those new active substances whose manufacturers had obtained Product Licences between 1972 and 1994 were sought from the Medicines Control Agency's product data-base. For each substance relevant information was retrieved including the year of granting the Product Licence, its therapeutic class, whether currently authorised (and, if not, reason for withdrawal), and its nature (chemical, biological etc.). Results The Medicines Control Agency's data-base was cross-checked against two other data-bases for completeness. A total of 583 new active substances (in 579 products) were found to have been authorised over the study period. The annual rates of authorisation varied widely (9 to 40 per year). Whilst there was no evidence for any overall change in the annual rates of authorising new chemical entities, there has been a trend for increasing numbers of new products of biological origin to be authorised in recent years. Fifty-nine of the 583 new active substances have been withdrawn (1 each for quality and efficacy, 22 for safety, and 35 for commercial reasons). Conclusions For reasons that are unclear there is marked heterogeneity in the annual rates of authorisation of new active substances. Their 10 year survival is approximately 88% with withdrawals being, predominantly, for commercial or safety reasons. This confirms the provisional nature of assessments about safety at the time when a new active substance is introduced into routine clinical practice, and emphasises the importance of pharmacovigilance.

The Keap1-Nrf2 Cellular Defense Pathway: Mechanisms of Regulation and Role in Protection Against Drug-Induced Toxicity

“…Adverse drug reactions constitute a major cause of patient morbidity and mortality (Park et al 2005), and they have been responsible for the withdrawal of 4% of all drugs licensed in the United Kingdom between 1974 and 1994 (Jefferys et al 1998). Therefore, adverse drug reactions pose a significant public health problem.…”

Glucuronidation of Drugs and Drug-Induced Toxicity in HumanizedUDP-Glucuronosyltransferase 1Mice

“…ADRs may preclude effective drug therapy. If ADRs are quite serious, they may occasionally lead to drug withdrawal (Jefferys et al, 1998). For instance, zomepirac was withdrawn on March 4, 1983, relatively soon after its November 1980 market release, due to unexplained fatal anaphylactic reactions (Ross-Degnan et al, 1993).…”

Farmacogenética: Princípios, Aplicações E Perspectivas

“…Sabe-se que nos Estados Unidos, mais de dois milhões de hospitalizações e 100.000 mortes por ano são decorrentes de reações adversas a medicamentos 1 . Ainda, aproximadamente 4% de todos os novos medicamentos lançados são retirados do mercado devido às reações adversas 2 , configurando uma situação desastrosa para a indústria farmacêuti-ca, que gasta milhões de dólares para desenvolver um novo produto. Dessa forma, se faz importante estudar os aspectos que podem influenciar as respostas aos medicamentos e os fatores que podem levar às reações adversas.…”